Patents Assigned to Cornell University
  • Patent number: 11250363
    Abstract: A processing device is configured to detect arrival of at least a particular user in a group of a plurality of users competing for designated resources of a system, and responsive to the detected arrival, to solve a resource allocation optimization problem that considers individualized characteristics of user resource allocation requests of respective ones of the users to obtain potential assignments of respective ones of the users to respective ones of the resources. The processing device is further configured to update one or more game model parameters based at least in part on the solution to the resource allocation optimization problem, to update a specified look-ahead function based at least in part on the one or more updated game model parameters, and to assign the particular user to a particular one of the resources based at least in part on a difference between an updated value of the look-ahead function and a previous value of the look-ahead function.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: February 15, 2022
    Assignee: Cornell University
    Inventors: Hamid R. Sayarshad, Shahram Sattar
  • Patent number: 11246946
    Abstract: Described herein is a method of induced cell death via ferroptosis by nanoparticle ingestion. Moreover, the present disclosure describes the administration of high concentrations of ultrasmall nanoparticles at multiple times over the course of treatment in combination with a nutrient-depleted environment, thereby modulating cellular metabolic pathways to induce cell death by the mechanism ferroptosis. Ferroptosis involves iron, reactive oxygen species, and a synchronous mode of cell death execution.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: February 15, 2022
    Assignees: Memorial Sloan Kettering Cancer Center, Cornell University
    Inventors: Michelle S. Bradbury, Ulrich Wiesner, Michael Overholtzer, Howard Scher, Kai Ma
  • Patent number: 11248007
    Abstract: Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-?B signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: February 15, 2022
    Assignees: Cornell University, Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, David A. Scott, John Hatcher, Ari M. Melnick, Lorena Fontan Gabas
  • Patent number: 11244309
    Abstract: An apparatus in an illustrative embodiment comprises a processing platform that includes one or more processing devices each comprising a processor coupled to a memory. The processing platform is configured to communicate over at least one network with one or more additional sets of processing devices associated with at least a first blockchain-based cryptocurrency system. Each of at least a subset of the one or more processing devices of the processing platform comprises a trusted execution environment, such as a secure enclave.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 8, 2022
    Assignee: Cornell University
    Inventors: Iddo Bentov, Ari Juels, Fan Zhang, Philip Daian, Lorenz Breidenbach
  • Patent number: 11243229
    Abstract: An atomic force microscope includes a cantilever operating in amplitude modulation mode. A controller determines the amplitude of the cantilever oscillation by processing a signal representative of the cantilever motion by square-rooting a signal having a value substantially equal to a sum of a square of the received signal and a squared and phase-shifted version of the received signal. The aforementioned processing, in some implementations is implemented using analog circuit components.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: February 8, 2022
    Assignee: Cornell University
    Inventors: Atsushi Miyagi, Simon Scheuring
  • Publication number: 20220016277
    Abstract: The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following Formulas (I), or a pharmaceutically acceptable salt thereof (IA), or a pharmaceutically acceptable salt thereof (II), or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
    Type: Application
    Filed: November 20, 2019
    Publication date: January 20, 2022
    Applicant: Cornell University
    Inventors: John W. Babich, Justin WILSON, Nikki THIELE, James M. Kelly, Shashikanth Ponnala
  • Publication number: 20220007992
    Abstract: A computer-implemented method for pelvic floor feedback. The method includes capturing a strength of action potentials via wireless sensors, the wireless sensors positioned proximate to a pelvic floor of a user. The method also includes transmitting the strength of the action potentials to a mobile device. The method also includes recording the strength of the action potentials on the mobile device.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 13, 2022
    Applicant: Cornell University
    Inventors: Jeremy B. WIYGUL, Saie Milind GANOO, Rohit CURUCUNDHI
  • Patent number: 11215621
    Abstract: A processing platform in one embodiment comprises one or more processing devices each including at least one processor coupled to a memory. The processing platform is configured to implement a crosslink identification and validation algorithm for processing multiple levels of mass spectrometry data in order to identify and validate protein-protein interactions within the mass spectrometry data. In conjunction with execution of the crosslink identification and validation algorithm, the processing platform is further configured to obtain mass spectrometry spectra for each of the multiple levels, to apply a header matching filter to identify at least one potential crosslink relating one or more first level spectra and one or more second level spectra utilizing a plurality of third level spectra, and to apply one or more mass validation filters to identify whether or not the potential crosslink is a valid crosslink.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 4, 2022
    Assignee: Cornell University
    Inventors: Haiyuan Yu, Sheng Zhang, Yugandhar Kumar, Ievgen Motorykin
  • Patent number: 11217700
    Abstract: Micron scale tin oxide-based semiconductor devices are provided. Reactive-ion etching is used to produce a micron-scale electronic device using semiconductor films with tin oxides, such as barium stannate (BaSnO3). The electronic devices produced with this approach have high mobility, drain current, and on-off ratio without adversely affecting qualities of the tin oxide semiconductor, such as resistivity, electron or hole mobility, and surface roughness. In this manner, electronic devices, such as field-effect transistors (e.g., thin-film transistors (TFTs)), are produced having micron scale channel lengths and exhibiting complete depletion at room temperature.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: January 4, 2022
    Assignee: Cornell University
    Inventor: Jisung Park
  • Patent number: 11202817
    Abstract: The compounds of the present invention are represented by the following compounds having Formula I: where the substituents R1, R4, L, M, X, Y, and s are as defined herein. The compounds of the present invention are also represented by the following compounds having Formula (Ia), Formula (Ib), or Formula (Ic): where the substituents R1-R4, Rx, Ry, X, Y, and s are as defined herein. These compounds are used in the treatment of cancer, immunologic disorders, autoimmune disorders, neurodegenerative disorders, or inflammatory disorders or for providing immunosuppression for transplanted organs or tissues.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: December 21, 2021
    Assignee: Cornell University
    Inventors: Gang Lin, Carl Nathan, Pradeep K. Singh
  • Publication number: 20210388018
    Abstract: The invention provides a compound of formula (I): (I) wherein R is methyl or ethyl. The invention also provides a process for the preparation of the compound. The invention further provides a method for increasing cell NAD+ production or improving mitochondrial densities in a cell, wherein the method comprises administering to the cell a compound or salt of the invention.
    Type: Application
    Filed: October 1, 2019
    Publication date: December 16, 2021
    Applicant: Cornell University
    Inventor: Anthony A. Sauve
  • Publication number: 20210384362
    Abstract: Described herein are the design and fabrication of Group III trioxides, such as ?-Ga2O3, trench-MOS barrier Schottky (TMBS) structures with high voltage (>1 kV), low leakage capabilities, while addressing on the necessary methods to meet the re-quirements unique to Group III trioxides, such as ?-Ga2O3.
    Type: Application
    Filed: October 30, 2019
    Publication date: December 9, 2021
    Applicant: Cornell University
    Inventors: Wenshen Li, Zongyang Hu, Kazuki Nomoto, Debdeep Jena, Huili Grace Xing
  • Patent number: 11191755
    Abstract: The invention provides compositions and methods for providing a cardioprotective effect in a subject. Specifically, the invention provides compositions and methods for treating cardiovascular ailments, for example, ischemia/reperfusion (I/R) injury, cardiac arrhythmias, oxidative stress, or cardiac failure by administering a retinoic acid receptor-beta (RAR?) agonist.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: December 7, 2021
    Assignee: Cornell University
    Inventors: Lorraine J Gudas, Xiao-Han Tang
  • Patent number: 11192942
    Abstract: The present invention relates to an isolated chimeric molecule comprising a degradation domain including a eukaryotic U-box motif and a targeting domain capable of immunospecifically directing the degradation domain to a substrate where the targeting domain is heterologous to the degradation domain. A linker couples the degradation domain to the targeting domain. Also disclosed are compositions as well as methods of treating a disease, substrate silencing, screening agents for therapeutic efficacy against a disease, and methods of screening for disease biomarkers.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: December 7, 2021
    Assignee: Cornell University
    Inventors: Matthew DeLisa, Jeffrey Varner, Alyse Portnoff
  • Patent number: 11191530
    Abstract: A method and device for facilitating the anastomotic healing of a patient after a radical prostatectomy surgical procedure, without a urethral catheter, comprising the steps of performing a radical prostatectomy, fixedly positioning a splinting element between the urethra and the bladder, across the urethral opening, placing the splinting element during the performing of the radical prostatectomy and prior to surgical closure. The fixed positioning is effected from a position within the bladder with anchoring the splinting element in position relative to the interior of the bladder, setting a separate urine drainage tube, and removing the splinting element, after anastomotic healing, with a retrieval element on the splinting element or with dissolving of the splinting element.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: December 7, 2021
    Assignee: Cornell University
    Inventor: Ashutosh K. Tewari
  • Patent number: 11189699
    Abstract: Provided are a superlattice structure including a two-dimensional material and a device including the superlattice structure. The superlattice structure may include at least two different two-dimensional (2D) materials bonded to each other in a lateral direction, and an interfacial region of the at least two 2D materials may be strained. The superlattice structure may have a bandgap adjusted by the interfacial region that is strained. The at least two 2D materials may include first and second 2D materials. The first 2D material may have a first bandgap in an intrinsic state thereof. The second 2D material may have a second bandgap in an intrinsic state thereof. An interfacial region of the first and second 2D materials and an adjacent region may have a third bandgap between the first bandgap and the second bandgap.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: November 30, 2021
    Assignees: Samsung Electronics Co., Ltd., Center for Technology Licensing at Cornell University, The University of Chicago
    Inventors: Minhyun Lee, Jiwoong Park, Saien Xie, Jinseong Heo, Hyeonjin Shin
  • Patent number: 11186841
    Abstract: Provided are compositions and methods for prophylaxis or therapy for human immunodeficiency virus (HIV) infection. The compositions and methods involve use of RNAi agents targeted to an anti-apoptotic long non-coding RNA (lncRNA) that is IncRNA SAF (FAS-AS1) or HOXA-AS2. The RNAi agents preferentially induce apoptosis of HIV infected macrophages. RNAi agents, and macrophages containing the RNAi agents, are also provided.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: November 30, 2021
    Assignee: Cornell University
    Inventor: David G. Russell
  • Patent number: 11179884
    Abstract: Systems and methods are provided for incremental 3D printing, wherein wireframes are generated and printed (scheduled for print) during the design process. In another aspect, systems and methods are provided for printing arbitrary meshes. A 3D printer system is described having, for example, five degree-of-freedom (5DOF). The 5DOF printer may be used to perform any of the methods described herein and combinations of the methods.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: November 23, 2021
    Assignee: Cornell University
    Inventors: Francois Guimbretiere, Huaishu Peng, Stephen Robert Marschner, Rundong Wu
  • Publication number: 20210353657
    Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
    Type: Application
    Filed: July 27, 2021
    Publication date: November 18, 2021
    Applicant: Cornell University
    Inventors: Anthony A. Sauve, Tianle Yang Redanz
  • Publication number: 20210355152
    Abstract: Disclosed is a compound of formula (I): wherein R1, R2, R3, and are as defined herein. Also disclosed are methods for increasing mammalian cell NAD+ production and improving mitochondrial cell densities comprising administering to a cell the compound or a salt thereof.
    Type: Application
    Filed: July 27, 2021
    Publication date: November 18, 2021
    Applicant: Cornell University
    Inventors: Anthony Sauve, Farheen Sultana Mohammed, Yue Yang